<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: We sought to compare the safety and efficacy of direct urokinase thrombolysis with systemic <z:chebi fb="5" ids="28304">heparin</z:chebi> anticoagulation for superior sagittal sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> (SSST) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: At University at Buffalo (NY) and University of Texas (Dallas, Houston), we reviewed 40 consecutive patients with SSST, treated with local urokinase (thrombolysis group) or systemic <z:chebi fb="5" ids="28304">heparin</z:chebi> anticoagulation (<z:chebi fb="5" ids="28304">heparin</z:chebi> group) </plain></SENT>
<SENT sid="2" pm="."><plain>The thrombolysis group (n=20) received local urokinase into the SSS followed by systemic <z:chebi fb="5" ids="28304">heparin</z:chebi> anticoagulation </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="5" ids="28304">heparin</z:chebi> group (n=20) received systemic <z:chebi fb="5" ids="28304">heparin</z:chebi> anticoagulation only </plain></SENT>
<SENT sid="4" pm="."><plain>Neurological dysfunction was rated as follows: 0, <z:mpath ids='MPATH_458'>normal</z:mpath>; 1, mild (but able to ambulate and communicate); 2, moderate (unable to ambulate, <z:mpath ids='MPATH_458'>normal</z:mpath> mentation); and 3, severe (unable to ambulate, altered mentation) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Age (P=0.49), sex (P=0.20), baseline venous infarction (P=0.73), and predisposing illnesses (P=0.52) were similar between the thrombolysis and <z:chebi fb="5" ids="28304">heparin</z:chebi> groups </plain></SENT>
<SENT sid="6" pm="."><plain>Pretreatment neurological function was worse in the thrombolysis group (<z:mpath ids='MPATH_458'>normal</z:mpath>, n=5; mild, n=8; moderate, n=4; severe, n=3) than in the <z:chebi fb="5" ids="28304">heparin</z:chebi> group (<z:mpath ids='MPATH_458'>normal</z:mpath>, n=8; mild, n=8; moderate, n=3; severe, n=1) (P=NS) </plain></SENT>
<SENT sid="7" pm="."><plain>Discharge neurological function was better in the thrombolysis group (<z:mpath ids='MPATH_458'>normal</z:mpath>, n=16; mild, n=3; moderate, n=1; severe, n=0) than in the <z:chebi fb="5" ids="28304">heparin</z:chebi> group (<z:mpath ids='MPATH_458'>normal</z:mpath>, n=9; mild, n=6; moderate, n=5; severe, n=0) (P=0.019, Mann-Whitney U test) </plain></SENT>
<SENT sid="8" pm="."><plain>Hemorrhagic complications were 10% (n=2) in the thrombolysis group (<z:hpo ids='HP_0100309'>subdural hematoma</z:hpo>, retroperitoneal <z:mp ids='MP_0001914'>hemorrhage</z:mp>) and none in the <z:chebi fb="5" ids="28304">heparin</z:chebi> group (P=0.49) </plain></SENT>
<SENT sid="9" pm="."><plain>Three of the <z:chebi fb="5" ids="28304">heparin</z:chebi> group patients developed complications of the underlying disease (<z:hpo ids='HP_0002133'>status epilepticus</z:hpo>, <z:hpo ids='HP_0000238'>hydrocephalus</z:hpo>, refractory <z:hpo ids='HP_0001085'>papilledema</z:hpo>) </plain></SENT>
<SENT sid="10" pm="."><plain>No <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred </plain></SENT>
<SENT sid="11" pm="."><plain>Length of hospital stay was similar between the groups (P=0.79) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Local thrombolysis with urokinase is fairly well tolerated and may be more effective than systemic <z:chebi fb="5" ids="28304">heparin</z:chebi> anticoagulation alone in treating SSST </plain></SENT>
<SENT sid="13" pm="."><plain>A randomized, prospective study comparing these 2 treatments for SSST is warranted </plain></SENT>
</text></document>